Technology evaluation: alicaforsen (Isis).
Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.
Gewirtz
Andrew T
AT
Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, GA 30322, USA. agewirt@emory.edu
Sitaraman
Shanthi V
SV
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D020319:Oligodeoxyribonucleotides, Antisense / Q000009:adverse effects / Q000627:therapeutic use*; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides / Q000009:adverse effects / Q000627:therapeutic use*
D020319:Oligodeoxyribonucleotides, Antisense; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides; C089753:alicaforsen